As we navigate current socio-economic and environmental challenges, we must prioritise building sustainable, resilient and equitable health systems that protect current and future generations. During 2022, AstraZeneca demonstrated its continued commitment to innovate for patients and improve health outcomes worldwide. Our pandemic response and global vaccine delivery are testament to this, with over six million lives saved in the first year1 and a focus on equitable access. We are making important progress with our science-led Ambition Zero Carbon strategy. We also continued to drive change across the health sector, including through the Sustainable Markets Initiative (SMI). Ahead of COP27, the SMI Health Systems Task Force, which I am honoured to champion, announced shared commitments and actions to reduce emissions in line with the 1. 5°C pathway and accelerate the transition to net-zero health systems. Furthermore, the Partnership for Health System Sustainability and Resilience (PHSSR), which we co-founded in 2020, has now expanded to more than 30 countries. Our top three ranking in the 2022 Access to Medicine Index recognises our strategic focus on increasing equitable and affordable access to life-changing treatments. How we achieve results is of vital importance, and we are guided by our Values in all that we do. Through our Code of Ethics and standards, we strive for a safe, responsible and ethical business culture for our employees and partners.